These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 760446)

  • 1. Heparin therapy: a randomized prospective study.
    Wilson JR; Lampman J
    Am Heart J; 1979 Feb; 97(2):155-8. PubMed ID: 760446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized prospective trial of continuous vs intermittent heparin therapy.
    Glazier RL; Crowell EB
    JAMA; 1976 Sep; 236(12):1365-7. PubMed ID: 989091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemorrhagic complications of heparin therapy.
    Mant MJ; O'Brien BD; Thong KL; Hammond GW; Birtwhistle RV; Grace MG
    Lancet; 1977 May; 1(8022):1133-5. PubMed ID: 68228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin therapy in venous thromboembolism.
    Wilson JE; Bynum LJ; Parkey RW
    Am J Med; 1981 Apr; 70(4):808-16. PubMed ID: 7211918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of heparin therapy: Controlled prospective trial.
    Salzman EW; Deykin D; Shapiro RM; Rosenberg R
    N Engl J Med; 1975 May; 292(20):1046-50. PubMed ID: 1091856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control and complications of intermittent heparin therapy.
    Norman CS; Provan JL
    Surg Gynecol Obstet; 1977 Sep; 145(3):338-42. PubMed ID: 888052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant treatment of thromboembolism with intravenous heparin therapy in the early postoperative period following total joint arthroplasty.
    Della Valle CJ; Jazrawi LM; Idjadi J; Hiebert RN; Stuchin SA; Steiger DJ; Di Cesare PE
    J Bone Joint Surg Am; 2000 Feb; 82(2):207-12. PubMed ID: 10682729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory control of heparin therapy.
    O'Shea MJ; Flute PT; Pannell GM
    J Clin Pathol; 1971 Sep; 24(6):542-6. PubMed ID: 5094686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of heparin therapy after total joint arthroplasty.
    Patterson BM; Marchand R; Ranawat C
    J Bone Joint Surg Am; 1989 Sep; 71(8):1130-4. PubMed ID: 2777838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
    Albada J; Nieuwenhuis HK; Sixma JJ
    Circulation; 1989 Oct; 80(4):935-40. PubMed ID: 2551537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.
    Raschke RA; Reilly BM; Guidry JR; Fontana JR; Srinivas S
    Ann Intern Med; 1993 Nov; 119(9):874-81. PubMed ID: 8214998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for bleeding during treatment of acute venous thromboembolism.
    Wester JP; de Valk HW; Nieuwenhuis HK; Brouwer CB; van der Graaf Y; Meuwissen OJ; Hart HC; Sixma JJ; Banga JD
    Thromb Haemost; 1996 Nov; 76(5):682-8. PubMed ID: 8950773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further hazards of heparin therapy in vascular surgery.
    Ariyan S; Stansel HC
    Arch Surg; 1976 Feb; 111(2):120-1. PubMed ID: 1252116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroergotamine/heparin in the prevention of deep-vein thrombosis after total hip replacement. A controlled, prospective, randomized multicenter trial.
    Beisaw NE; Comerota AJ; Groth HE; Merli GJ; Weitz HH; Zimmerman RC; Diserio FJ; Sasahara AA
    J Bone Joint Surg Am; 1988 Jan; 70(1):2-10. PubMed ID: 3275673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet count and the risk of bleeding in hospitalized patients with venous thromboembolism starting anticoagulant therapy.
    Monreal M; Urrutia A; Marti S; Cuxart A; Roncales J
    Haemostasis; 1997; 27(2):91-8. PubMed ID: 9212357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin infusion after successful percutaneous coronary intervention: a prospective, randomized trial.
    Zibaeenezhad MJ; Mazloum Y
    Acta Cardiol; 2009 Feb; 64(1):65-70. PubMed ID: 19317300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.